Dafna Capital Management adds Novavax (NVAX) to its portfolio

Novavax (NVAX) : Dafna Capital Management added new position in Novavax during the most recent quarter end. The investment management firm now holds 553,500 shares of Novavax which is valued at $3,896,640 , the company said in a statement filed on Aug 15, 2016 with the SEC.Novavax makes up approximately 3.08% of Dafna Capital Management’s portfolio.

Other Hedge Funds, Including , Two Sigma Investments Lp added NVAX to its portfolio by purchasing 13,700 company shares during the most recent quarter which is valued at $96,448.Tiaa Cref Investment Management reduced its stake in NVAX by selling 18,957 shares or 1.94% in the most recent quarter. The Hedge Fund company now holds 959,220 shares of NVAX which is valued at $6,752,909. Focused Wealth Management Inc added NVAX to its portfolio by purchasing 500 company shares during the most recent quarter which is valued at $7,040.Victory Capital Management Inc boosted its stake in NVAX in the latest quarter, The investment management firm added 153 additional shares and now holds a total of 3,894 shares of Novavax which is valued at $26,713. Alpha Cubed Investments sold out all of its stake in NVAX during the most recent quarter. The investment firm sold 13,000 shares of NVAX which is valued $99,320.

Novavax closed down -0.02 points or -0.29% at $6.82 with 27,66,439 shares getting traded on Thursday. Post opening the session at $6.85, the shares hit an intraday low of $6.705 and an intraday high of $6.89 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Novavax reported $-0.29 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.25. The company had revenue of $2.50 million for the quarter, compared to analysts expectations of $8.10 million. The company’s revenue was down -82.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.08 EPS.

Novavax Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV) seasonal influenza pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications Matrix-M is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases including Middle East respiratory syndrome (MERS).

Leave a Reply

Novavax - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novavax. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.